Caribou Biosciences

(NASDAQ) CRBU

Current Price$2.06

Market Cap$188.09M

Since IPO (2021)-88%

5 YearN/A

1 Year+146%

1 Month-1%

Caribou Biosciences Financials at a Glance

Market Cap

$188.09M

Revenue (TTM)

$11.20M

Net Income (TTM)

$133.22M

EPS (TTM)

$-1.42

P/E Ratio

-1.37

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$2.06

Volume

1,654,304.046

Open

$1.97

Price

$2.06

Volume

1,654,304.046

Open

$1.97

Previous Close

$1.94

Daily Range

$1.95 - $2.19

52-Week Range

$0.77 - $3.54

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$2.06

Volume

1,654,304.046

Open

$1.97

Previous Close

$1.94

Daily Range

$1.95 - $2.19

52-Week Range

$0.77 - $3.54

CRBU News

DNA with a section separated from the main part.

A Bull Market Is Coming: 1 Beaten-Down Growth Stock You Could Regret Not Buying on the Dip

Cory RenauerOct 10, 2023

Page 1

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Caribou Biosciences

Industry

Biotechnology

Sector

Health Care

Employees

CEO

Rachel E. Haurwitz, PhD

Website

www.cariboubio.com

Headquarters

Berkeley, CA 94710, US

CRBU Financials

Key Financial Metrics (TTM)

Gross Margin

82%

Operating Margin

-12%

Net Income Margin

-12%

Return on Equity

-83%

Return on Capital

-1%

Return on Assets

-89%

Earnings Yield

-72.99%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$188.09M

Shares Outstanding

96.95M

Volume

1.65M

Avg. Volume

1.33M

Financials (TTM)

Gross Profit

$7.51M

Operating Income

$136.19M

EBITDA

$132.55M

Operating Cash Flow

$110.99M

Capital Expenditure

$1.36M

Free Cash Flow

$112.35M

Cash & ST Invst.

$139.34M

Total Debt

$27.23M

Caribou Biosciences Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$2.40M

+1.9%

Gross Profit

$1.75M

-25.7%

Gross Margin

72.92%

N/A

Market Cap

$188.09M

N/A

Market Cap/Employee

$1.28M

N/A

Employees

147

N/A

Net Income

$25.09M

+37.3%

EBITDA

$26.28M

+37.1%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Net Cash

$90.68M

-50.2%

Accounts Receivable

$2.36M

-13.8%

Inventory

$0.00

N/A

Long Term Debt

$25.66M

+5.5%

Short Term Debt

$1.29M

-32.3%

Return on Assets

-89.41%

N/A

Return on Invested Capital

-1.02%

N/A

Free Cash Flow

$27.06M

+28.4%

Operating Cash Flow

$26.98M

+26.5%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

PYXSPyxis Oncology, Inc.

PYXSPyxis Oncology, Inc.$2.81+2.37%

TNYATenaya Therapeutics, Inc.

TNYATenaya Therapeutics, Inc.$1.01+1.00%

HUMAHumacyte, Inc.

HUMAHumacyte, Inc.$1.03-2.83%

OBIOOrchestra BioMed Holdings, Inc.

OBIOOrchestra BioMed Holdings, Inc.$3.96-1.96%

AARDAardvark Therapeutics, Inc. Common Stock

AARDAardvark Therapeutics, Inc. Common Stock$5.60+3.00%

FHTXFoghorn Therapeutics Inc.

FHTXFoghorn Therapeutics Inc.$4.37-1.58%

PRLDPrelude Therapeutics Incorporated

PRLDPrelude Therapeutics Incorporated$4.88+0.36%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$16.91+0.08%

SQQQProShares Trust - ProShares UltraPro Short Qqq

SQQQProShares Trust - ProShares UltraPro Short Qqq$42.09-0.01%

ODYSOdysight.ai

ODYSOdysight.ai$5.20+0.17%

TSDDGraniteShares ETF Trust - GraniteShares 2x Short Tsla Daily ETF

TSDDGraniteShares ETF Trust - GraniteShares 2x Short Tsla Daily ETF$6.83-0.08%

DGXXDigi Power X

DGXXDigi Power X$7.64+0.15%

MARAMara Holdings

MARAMara Holdings$13.73+0.06%

NOKNokia

NOKNokia$13.92+0.09%

Questions About CRBU

What is the current price of Caribou Biosciences?

Caribou Biosciences is trading at $2.06 per share.

What is the 52-week range for Caribou Biosciences?

Over the past 52 weeks, Caribou Biosciences has traded between $0.77 and $3.54.

How much debt does Caribou Biosciences have?

As of the most recent reporting period, Caribou Biosciences reported total debt of $26.95M.

How much cash does Caribou Biosciences have on hand?

Caribou Biosciences reported $12.06M in cash and cash equivalents in its most recent financial results.

What is Caribou Biosciences’s dividend yield?

Caribou Biosciences does not currently have a dividend yield.

Caribou Biosciences

Caribou Biosciences Financials at a Glance

CRBU News

Best CRISPR Gene Editing ETFs for 2026 and How to Invest

Best Gene Editing Stocks for 2026 and How to Invest

Best CRISPR Companies to Buy in 2026 and How to Invest in Them

Why Caribou Biosciences Stock Is Crashing Today

Missed Out on CRISPR Therapeutics? My Best Gene-Editing Stock to Buy and Hold

2 Risky Gene-Editing Stocks to Buy in the New Bull Market if You Dare

2 Exciting Biotech Stocks to Buy With Less Than $10

A Bull Market Is Coming: 1 Beaten-Down Growth Stock You Could Regret Not Buying on the Dip

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Caribou Biosciences

CRBU Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Caribou Biosciences Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About CRBU

What is the current price of Caribou Biosciences?

What is the 52-week range for Caribou Biosciences?

How much debt does Caribou Biosciences have?

How much cash does Caribou Biosciences have on hand?

What is Caribou Biosciences’s dividend yield?

Premium Investing Services